Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
8d agoen
From the article
Conditions : Esophageal Squamous Cell Carcinoma (ESCC) Interventions : Drug: Albumin-bound paclitaxel; Radiation: Low-dose Short-course Radiotherapy; Radiation: High-dose Short-course Radiotherapy; Drug: Tislelizumab Combined With Chemotherapy for 3 cycles; Drug: Carboplatin (AUC 5) Sponsors : Tang-Du Hospital Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
ClinicalKey
clinicalkey.com·1mo ago
Dose-reduced thoracic radiotherapy shows promise for older and frail stage III NSCLC patients in randomized trial
This randomized open-label cohort trial by Wei-Xiang Qi and colleagues investigates whether dose-reduced thoracic radiotherapy can mitigate
plos.io·1mo ago
New drug for cancer patients with ‘limited’ treatment options enters clinical trial
The Independent·3d ago
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK·17y ago
La creatina no solo desarrolla músculo: un estudio revela su potencial para fortalecer la inmunoterapia contra el cáncer
Infobae·7h ago
Lipid nanoparticle platform delivers chemo drug and RNA to boost immune response against lung cancer
Researchers at the University of Arizona have developed a nanotechnology-based platform using lipid nanoparticles to deliver a chemotherapy
news-medical.net·12d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.